Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2011

Open Access 01-12-2011 | Research

Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells

Authors: Juan Liu, Hiroshi Uematsu, Nobuo Tsuchida, Masa-Aki Ikeda

Published in: Molecular Cancer | Issue 1/2011

Login to get access

Abstract

Background

Caspase-8 is a key upstream mediator in death receptor-mediated apoptosis and also participates in mitochondria-mediated apoptosis via cleavage of proapoptotic Bid. However, the role of caspase-8 in p53- and p73-dependent apoptosis induced by genotoxic drugs remains unclear. We recently reported that the reconstitution of procaspase-8 is sufficient for sensitizing cisplatin- but not etoposide-induced apoptosis, in chemoresistant and caspase-8 deficient HOC313 head and neck squamous cell carcinoma (HNSCC) cells.

Results

We show that p53/p73-dependent caspase-8 activation is required for sensitizing etoposide-induced apoptosis by utilizing HOC313 cells carrying a temperature-sensitive p53G285K mutant. Restoration of wild-type p53 function under the permissive conditions, together with etoposide treatment, led to substantial transcriptional activation of proapoptotic Noxa and PUMA, but failed to induce apoptosis. In addition to p53 restoration, caspase-8 reconstitution was needed for sensitization to etoposide-induced apoptosis, mitochondria depolarization, and cleavage of the procaspases-3, and -9. In etoposide-sensitive Ca9-22 cells carrying a temperature-insensitive mutant p53, siRNA-based p73 knockdown blocked etoposide-induced apoptosis and procaspase-8 cleavage. However, induction of p73 protein and up-regulation of Noxa and PUMA, although observed in Ca9-22 cells, were hardly detected in etoposide-treated HOC313 cells under non-permissive conditions, suggesting a contribution of p73 reduction to etoposide resistance in HOC313 cells. Finally, the caspase-9 inhibitor Ac-LEHD-CHO or caspase-9 siRNA blocked etoposide-induced caspase-8 activation, Bid cleavage, and apoptosis in both cell lines, indicating that p53/p73-dependent caspase-8 activation lies downstream of mitochondria.

Conclusions

we conclude that p53 and p73 can act as upstream regulators of caspase-8, and that caspase-8 is an essential mediator of the p53/p73-dependent apoptosis induced by etoposide in HNSCC cells. Our data suggest the importance of caspase-8-mediated positive feedback amplification in the p53/p73-dependent apoptosis induced by etoposide in HNSCC cells.
Appendix
Available only for authorised users
Literature
1.
Danial NN, Korsmeyer SJ: Cell death: critical control points. Cell. 2004, 116: 205-219. 10.1016/S0092-8674(04)00046-7CrossRefPubMed
2.
Boatright KM, Salvesen GS: Mechanisms of caspase activation. Curr Opin Cell Biol. 2003, 15: 725-731. 10.1016/j.ceb.2003.10.009CrossRefPubMed
3.
4.
Harris MH, Thompson CB: The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ. 2000, 7: 1182-1191. 10.1038/sj.cdd.4400781CrossRefPubMed
5.
Houghton JA, Harwood FG, Tillman DM: Thymineless death in colon carcinoma cells is mediated via fas signaling. Proc Natl Acad Sci USA. 1997, 94: 8144-8149. 10.1073/pnas.94.15.8144PubMedCentralCrossRefPubMed
6.
Friesen C, Fulda S, Debatin KM: Cytotoxic drugs and the CD95 pathway. Leukemia. 1999, 13: 1854-1858. 10.1038/sj.leu.2401333CrossRefPubMed
7.
Nomura Y, Inanami O, Takahashi K, Matsuda A, Kuwabara M: 2-Chloro-2'-deoxyadenosine induces apoptosis through the Fas/Fas ligand pathway in human leukemia cell line MOLT-4. Leukemia. 2000, 14: 299-306. 10.1038/sj.leu.2401649CrossRefPubMed
8.
Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G, Debatin KM: Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene. 2001, 20: 1063-1075. 10.1038/sj.onc.1204141CrossRefPubMed
9.
Fulda S, Küfer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM: Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 2001, 20: 5865-5877. 10.1038/sj.onc.1204750CrossRefPubMed
10.
Biswas RS, Cha HJ, Hardwick JM, Srivastava RK: Inhibition of drug-induced Fas ligand transcription and apoptosis by Bcl-XL. Mol Cell Biochem. 2001, 225: 7-20. 10.1023/A:1012203110027CrossRefPubMed
11.
Wesselborg S, Engels IH, Rossmann E, Los M, Schulze-Osthoff K: Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood. 1999, 93: 3053-3063.PubMed
12.
Ferreira CG, Span SW, Peters GJ, Kruyt FA, Giaccone G: Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res. 2000, 60: 7133-7141.PubMed
13.
Ferreira CG, Tolis C, Span SW, Peters GJ, van Lopik T, Kummer AJ, Pinedo HM, Giaccone G: Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin Cancer Res. 2000, 6: 203-212.PubMed
14.
Tang D, Lahti JM, Kidd VJ: Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis. J Biol Chem. 2000, 275: 9303-9307. 10.1074/jbc.275.13.9303CrossRefPubMed
15.
Pan J, Xu G, Yeung SC: Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel. J Clin Endocrinol Metab. 2001, 86: 4731-4740. 10.1210/jc.86.10.4731CrossRefPubMed
16.
de Vries JF, Wammes LJ, Jedema I, van Dreunen L, Nijmeijer BA, Heemskerk MH, Willemze R, Falkenburg JH, Barge RM: Involvement of caspase-8 in chemotherapy-induced apoptosis of patient derived leukemia cell lines independent of the death receptor pathway and downstream from mitochondria. Apoptosis. 2007, 12: 181-193. 10.1007/s10495-006-0526-6CrossRefPubMed
17.
Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, Dörken B, Daniel PT: Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood. 2001, 97: 1378-1387. 10.1182/blood.V97.5.1378CrossRefPubMed
18.
von Haefen C, Wieder T, Essmann F, Schulze-Osthoff K, Dörken B, Daniel PT: Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene. 2003, 22: 2236-2247. 10.1038/sj.onc.1206280CrossRefPubMed
19.
Sohn D, Schulze-Osthoff K, Jänicke RU: Caspase-8 can be activated by interchain proteolysis without receptor-triggered dimerization during drug-induced apoptosis. J Biol Chem. 2005, 280: 5267-5273.CrossRefPubMed
20.
Boesen-de Cock JG, Tepper AD, de Vries E, van Blitterswijk WJ, Borst J: Common regulation of apoptosis signaling induced by CD95 and the DNA-damaging stimuli etoposide and gamma-radiation downstream from caspase-8 activation. J Biol Chem. 1999, 274: 14255-14261. 10.1074/jbc.274.20.14255CrossRefPubMed
21.
Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM: Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem. 1999, 274: 5053-5060. 10.1074/jbc.274.8.5053CrossRefPubMed
22.
Perkins CL, Fang G, Kim CN, Bhalla KN: The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res. 2000, 60: 1645-1653.PubMed
23.
Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES: Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol. 1999, 144: 281-292. 10.1083/jcb.144.2.281PubMedCentralCrossRefPubMed
24.
Scaffidi C, Medema JP, Krammer PH, Peter ME: FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J Biol Chem. 1997, 272: 26953-26958. 10.1074/jbc.272.43.26953CrossRefPubMed
25.
Li H, Zhu H, Xu CJ, Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998, 94: 491-501. 10.1016/S0092-8674(00)81590-1CrossRefPubMed
26.
Luo X, Budihardjo I, Zou H, Slaughter C, Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998, 94: 481-490. 10.1016/S0092-8674(00)81589-5CrossRefPubMed
27.
Kuwana T, Smith JJ, Muzio M, Dixit V, Newmeyer DD, Kornbluth S: Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c. J Biol Chem. 1998, 273: 16589-16594. 10.1074/jbc.273.26.16589CrossRefPubMed
28.
Bossy-Wetzel E, Green DR: Caspases induce cytochrome c release from mitochondria by activating cytosolic factors. J Biol Chem. 1999, 274: 17484-17490. 10.1074/jbc.274.25.17484CrossRefPubMed
29.
Gross A, Yin XM, Wang K, Wei MC, Jockel J, Milliman C, Erdjument-Bromage H, Tempst P, Korsmeyer SJ: Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem. 1999, 274: 1156-1163. 10.1074/jbc.274.2.1156CrossRefPubMed
30.
Werner AB, de Vries E, Tait SW, Bontjer I, Borst J: TRAIL receptor and CD95 signal to mitochondria via FADD, caspase-8/10, Bid, and Bax but differentially regulate events downstream from truncated Bid. J Biol Chem. 2002, 277: 40760-40767. 10.1074/jbc.M204351200CrossRefPubMed
31.
Prives C, Hall PA: The p53 pathway. J Pathol. 1999, 187: 112-126. 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3CrossRefPubMed
32.
Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature. 2000, 408: 307-310. 10.1038/35042675CrossRefPubMed
33.
Oren M: Decision making by p53: life, death and cancer. Cell Death Differ. 2003, 10: 431-442. 10.1038/sj.cdd.4401183CrossRefPubMed
34.
Vousden KH, Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol. 2007, 8: 275-283. 10.1038/nrm2147CrossRefPubMed
35.
36.
Müller M, Schleithoff ES, Stremmel W, Melino G, Krammer PH, Schilling T: One, two, three--p53, p63, p73 and chemosensitivity. Drug Resist Updat. 2006, 9: 288-306. 10.1016/j.drup.2007.01.001CrossRefPubMed
37.
Oniscu A, Sphyris N, Morris RG, Bader S, Harrison DJ: p73alpha is a candidate effector in the p53 independent apoptosis pathway of cisplatin damaged primary murine colonocytes. J Clin Pathol. 2004, 57: 492-498. 10.1136/jcp.2003.012559PubMedCentralCrossRefPubMed
38.
Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG: Chemosensitivity linked to p73 function. Cancer Cell. 2003, 3: 403-410. 10.1016/S1535-6108(03)00078-3CrossRefPubMed
39.
Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A: p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003, 3: 387-402. 10.1016/S1535-6108(03)00079-5CrossRefPubMed
40.
Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW: p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell. 2006, 9: 45-56. 10.1016/j.ccr.2005.12.013CrossRefPubMed
41.
Kaneda Y, Shimamoto H, Matsumura K, Arvind R, Zhang S, Sakai E, Omura K, Tsuchida N: Role of caspase 8 as a determinant in chemosensitivity of p53-mutated head and neck squamous cell carcinoma cell lines. J Med Dent Sci. 2006, 53: 57-66.PubMed
42.
Liu J, Uematsu H, Tsuchida N, Ikeda MA: Association of caspase-8 mutation with chemoresistance to cisplatin in HOC313 head and neck squamous cell carcinoma cells. Biochem Biophys Res Commun. 2009, 390: 989-994. 10.1016/j.bbrc.2009.10.090CrossRefPubMed
43.
44.
Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y: p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 2000, 102: 849-862. 10.1016/S0092-8674(00)00073-8CrossRefPubMed
45.
Fanucchi S, Veale RB: Role of p53/FAK association and p53Ser46 phosphorylation in staurosporine-mediated apoptosis: wild type versus mutant p53-R175H. FEBS Lett. 2009, 583: 3557-3562. 10.1016/j.febslet.2009.10.059CrossRefPubMed
46.
Fischer B, Coelho D, Dufour P, Bergerat JP, Denis JM, Gueulette J, Bischoff P: Caspase 8-mediated cleavage of the pro-apoptotic BCL-2 family member BID in p53-dependent apoptosis. Biochem Biophys Res Commun. 2003, 306: 516-522. 10.1016/S0006-291X(03)01004-0CrossRefPubMed
47.
Liedtke C, Groger N, Manns MP, Trautwein C: The human caspase-8 promoter sustains basal activity through SP1 and ETS-like transcription factors and can be up-regulated by a p53-dependent mechanism. J Biol Chem. 2003, 278: 27593-27604. 10.1074/jbc.M304077200CrossRefPubMed
48.
Ehrhardt H, Häcker S, Wittmann S, Maurer M, Borkhardt A, Toloczko A, Debatin KM, Fulda S, Jeremias I: Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells. Oncogene. 2008, 27: 783-793. 10.1038/sj.onc.1210666CrossRefPubMed
49.
Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, Corazzari M, Knight RA, Green DR, Thompson C, Vousden KH: p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem. 2004, 279: 8076-8083.CrossRefPubMed
50.
Muscolini M, Cianfrocca R, Sajeva A, Mozzetti S, Ferrandina G, Costanzo A, Tuosto L: Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells. Mol Cancer Ther. 2008, 7: 1410-1419. 10.1158/1535-7163.MCT-08-0299CrossRefPubMed
51.
Ono Y, Nonomura N, Harada Y, Fukui T, Tokizane T, Sato E, Nakayama M, Nishimura K, Takahara S, Okuyama A: Loss of p73 induction in a cisplatin-resistant bladder cancer cell line. Mol Urol. 2001, 5: 25-30. 10.1089/109153601750124267CrossRefPubMed
52.
Chim CS, Liang R, Kwong YL: Hypermethylation of gene promoters in hematological neoplasia. Hematol Oncol. 2002, 20: 167-176. 10.1002/hon.694CrossRefPubMed
53.
Kim SB, Kim JS, Lee JH, Yoon WJ, Lee DS, Ko MS, Kwon BS, Choi DH, Cho HR, Lee BJ: NF-kappaB activation is required for cisplatin-induced apoptosis in head and neck squamous carcinoma cells. FEBS Lett. 2006, 580: 311-318. 10.1016/j.febslet.2005.12.012CrossRefPubMed
54.
Sakai E, Tsuchida N: Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene. 1992, 7: 927-933.PubMed
55.
Hirano Y, Yamato K, Tsuchida N: A temperature sensitive mutant of the human p53, Val138, arrests rat cell growth without induced expression of cip1/waf1/sdi1 after temperature shift-down. Oncogene. 1995, 10: 1879-1885.PubMed
Metadata
Title
Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells
Authors
Juan Liu
Hiroshi Uematsu
Nobuo Tsuchida
Masa-Aki Ikeda
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2011
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-10-95

Other articles of this Issue 1/2011

Molecular Cancer 1/2011 Go to the issue

Research

SOX2-RNAi attenuates S-phase entry and induces RhoA-dependent switch to protease-independent amoeboid migration in human glioma cells

Research

New Topoisomerase I mutations are associated with resistance to camptothecin

Review

Role of Bcl-3 in solid tumors

Research

Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer

Research

Overexpression of Aurora-A in primary cells interferes with S-phase entry by diminishing Cyclin D1 dependent activities

Research

Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits